The Cyclic AMP-GEF/C/EBP Pathway; a New PKA-independent Route for the Control of Gene Expression by Cyclic AMP

Lead Research Organisation: University of Glasgow
Department Name: School of Life Sciences

Abstract

The cyclic AMP cascade was the first intracellular mechanism described to explain how hormones exert functional changes inside cells and remains the archetypical signalling system. Until very recently in was thought that increases in the intracellular concentration of cyclic AMP exerted changes in the activity of genes solely through prior phosphorylation of the transription factor 'CREB' by the enzyme 'PKA'. However, a new route has now been discovered whereby cyclic AMP can activate proteins called Ras and Rap. These are involved in the control of cell survival, the cell cycle control and cell adhesion. However, in order to activate Ras and Rap, cyclic AMP must first directly interact with another class of enzymes called cyclic AMP GEFs. Two such cyclic AMP GEFs are EPAC or CNrasGEF. The aims of this project are to determine the mechanisms by which activation of cyclic AMP-GEFs can lead to changes in gene expression, in a cyclic AMP-dependent, independently of PKA. To do this we will use the SOCS-3 gene as a paradigm. SOCS-3 is a gene whose induction leads to the suppression of signaling from cytokine and growth factor receptors. We have recently found that the SOCS-3 gene is also positively regulated by cyclic AMP, through EPAC and Rap1. Our work shows that this is probably through transcription factors called C/EBP. Moreover, we have found that a PKA-independent pathway leads to the activation of the growth regulatory enzyme ERK from cyclic AMP. ERK is required for SOCS-3 induction by cyclic AMP and phosphorylates one class of C/EBPs, also in a cyclic AMP-dependent, PKA-independent fashion. We will therefore delineate this new pathway leading from activation of cyclic AMP-GEFs, like EPAC or CNrasGEF, through ERK to C/EBPs and determine the biological consequences of its activation in human umbilical cord endothelial cells (HUVECs). This cell system has been shown to express cyclic AMP-inducible SOCS-3 and presents the advantage that the biological significance of gene induction, as determined by SOCS-3 mediated inhibition of cytokine signalling, can be easily measured. Because the cyclic AMP-GEF-C/EBP pathway is the first example of a cyclic AMP-activated signalling pathway that can control gene expression independently of the classical PKA/CREB route, these studies are an urgent scientific priority. Our investigations will therefore provide a critical new understanding of how gene expression is regulated by the prototypical cyclic AMP signalling system. Our joint expertise in studying the molecular and cellular basis of cyclic AMP signalling means that we are well equipped to carry out these investigations.

Technical Summary

The aims of this project are to determine the mechanisms by which activation of cyclic AMP-GEFs, such as EPAC or CNrasGEF, lead to changes in gene expression in a protein kinase A (PKA)-independent manner using the SOCS-3 gene as a paradigm. We have obtained substantial preliminary data demonstrating that C/EBP transcription factors are activated by EPAC. Moreover, the induction of SOCS-3 is dependent on the prior activation of ERK, which promotes the phosphorylation of the C/EBP isoform, C/EBP beta, in a cyclic AMP-dependent, PKA-independent manner. This represents a fundamental new control mechanism by which cyclic AMP regulates gene transcription. Our objectives in this project therefore are to delineate this new cyclic AMP-GEF/C/EBP pathway and determine the biological consequences of its activation in a human umbilical cord endothelial cell (HUVEC) model system. These cells express EPAC-inducible SOCS-3 and have the benefit that the biological significance of gene induction, as determined by SOCS-3 mediated inhibition of IL-6 signaling through the JAK-STAT pathway, can be easily assessed. These studies are an urgent scientific priority because the cyclic AMP-GEF-C/EBP-SOCS-3 pathway represents the first example of a cyclic AMP-activated signalling pathway that can control gene expression independently of the classical route of cyclic AMP-mediated transcriptional control, via PKA and cyclic AMP-response-element-binding-proteins (CREB). Our investigations will therefore provide a critical new understanding of how gene expression is regulated by the prototypical cyclic AMP signalling system.

Publications

10 25 50
publication icon
Barker G (2017) The Potential of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation. in Journal of cardiovascular development and disease

publication icon
Borland G (2009) EPAC proteins transduce diverse cellular actions of cAMP. in British journal of pharmacology

 
Description 1) Activation of EPAC1 in vascular endothelial cells (VECs) leads to the induction of the SOCS-3 gene, which mediates anti-inflammatory actions of cyclic AMP in these cells. These findings now place EPAC1 at the centre of a regulatory network designed to limit inflammatory responses in
VECs.

2) SOCS-3 induction by EPAC1 requires C/EBP transcription factors, ß and d, which are activated by cyclic AMP, independently of the classical route through protein kinase A and CREB. This is a completely novel signalling pathway that has broad ramifications for a wide range of signalling
scenarios.

3) C/EBP activation and SOCS-3 induction by EPAC1 involves a new pathway including phospholipase Ce and protein kinase C isoforms a and d. We believe this new cyclic AMP regulated
signalling pathway can be exploited by novel therapeutics designed to treat cardiovascular disease. We have therefore begun collaboration with clinical researchers to test the
validity of this hypothesis.
Exploitation Route Our findings will support future research into EPAC1-directed drug research.
Sectors Pharmaceuticals and Medical Biotechnology

 
Description We have established EPAC1 as a valid drug-target in vascular endothelial cells. We are no developing a drug discovery program to realise this.
 
Description Biochemical Society - Chair of the Signal Transduction Theme Panel
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Biochemical Society - Council of the Biochemical Society. Member of Council
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
 
Description Marie Curie - Advisory Board for Institutional Fellowship
Geographic Reach Europe 
Policy Influence Type Participation in a guidance/advisory committee
 
Description Identification of Small Molecule Agonists
Amount £300,000 (GBP)
Funding ID ELFSC08_02 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2016 
End 01/2019
 
Description Identification of small molecule activators of EPAC1 to serve as novel anti-inflamatory agents in vascular endothelial cells
Amount £10,000 (GBP)
Organisation Scottish Universities Life Sciences Alliance 
Sector Academic/University
Country United Kingdom
Start 10/2011 
End 10/2012
 
Description James Watt PhD Studentship
Amount £80,000 (GBP)
Organisation Heriot-Watt University 
Sector Academic/University
Country United Kingdom
Start 11/2016 
End 10/2019
 
Description Mechanisms of regulation of the anti inflammatory gene SOCS3 by cyclic AMP
Amount £10,000 (GBP)
Organisation Tenovus Cancer Care 
Department Tenovus Scotland
Sector Charity/Non Profit
Country United Kingdom
Start 10/2006 
End 10/2007
 
Description Medical Research Scotland PhD Studentship
Amount £109,784 (GBP)
Funding ID PhD-868-2015 
Organisation Medical Research Scotland 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 06/2020
 
Description Novel EPAC1 inhibitors to enhance insulin sensitivity in vascular endothelial cells
Amount £107,122 (GBP)
Funding ID FS/17/12/32703 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description PhD Studentship
Amount £107,122 (GBP)
Funding ID FS/17/12/32703 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description Regulation of anti-inflammatory gene expression in vascular endothelial cells by EPAC1
Amount £220,852 (GBP)
Funding ID PG/15/15/31316 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2015 
End 10/2018
 
Description SOCS3 induction - a new physiological role for the cAMP sensor Epac in limiting endothelial dysfunction
Amount £162,924 (GBP)
Funding ID PG/05/026 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2005 
End 01/2008
 
Description The Role of EPAC1-regulated Protein Kinase C Isoforms in Mediating C/EBPdelta -dependent, Anti-inflammatory Actions of Cyclic AMP in Vascular Endothelial Cells
Amount £178,111 (GBP)
Funding ID pg/10/026/28303 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2010 
End 10/2013
 
Description The role of insulin-dependent signalling pathways in the control of mesenchymal stem cell differentiation towards bone and fat
Amount £10,000 (GBP)
Organisation Tenovus Cancer Care 
Department Tenovus Scotland
Sector Charity/Non Profit
Country United Kingdom
Start 10/2014 
End 10/2016
 
Description oThe EPAC-C/EBP pathway - a new route for the control of gene expression by cyclic AMP
Amount £416,289 (GBP)
Funding ID BB/D015324 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2005 
End 10/2009
 
Description BHF-funded Collaboration with Dr Tim Palmer 
Organisation University of Glasgow
Department Institute of Cardiovascular and Medical Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution We have a close collaboration with the Palmer laboratory and regularly share ideas and resources.
Collaborator Contribution Research resources
Impact Milne GR, Palmer TM, Yarwood SJ. Novel control of cAMP-regulated transcription in vascular endothelial cells. Biochem Soc Trans. 2012 Feb;40(1):1-5. Parnell E, Smith BO, Palmer TM, Terrin A, Zaccolo M, Yarwood SJ. Regulation of the inflammatory response of vascular endothelial cells by EPAC1. Br J Pharmacol. 2012 May;166(2):434-46. Sands WA, Woolson HD, Yarwood SJ, Palmer TM. Exchange protein directly activated by cyclic AMP-1-regulated recruitment of CCAAT/enhancer-binding proteins to the suppressor of cytokine signaling-3 promoter. Methods Mol Biol. 2012;809:201-14. Woolson HD, Thomson VS, Rutherford C, Yarwood SJ, Palmer TM. Selective inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via Epac1-dependent induction of suppressor of cytokine signalling-3. Cell Signal. 2009 Nov;21(11):1706-15. Borland G, Bird RJ, Palmer TM, Yarwood SJ. Activation of protein kinase Calpha by EPAC1 is required for the ERK- and CCAAT/enhancer-binding protein beta-dependent induction of the SOCS-3 gene by cyclic AMP in COS1 cells. J Biol Chem. 2009 Jun 26;284(26):17391-403. Yarwood SJ, Borland G, Sands WA, Palmer TM. Identification of CCAAT/enhancer-binding proteins as exchange protein activated by cAMP-activated transcription factors that mediate the induction of the SOCS-3 gene. J Biol Chem. 2008 Mar 14;283(11):6843-53.
Start Year 2012
 
Description European Lead Factory 
Organisation European Screening Centre (ESC)
Country United Kingdom 
Sector Public 
PI Contribution We devised a high throughput screening assay which was used to identify small molecule regulators of the enzyme, EPAC1
Collaborator Contribution ultra high throughput screening; protein purification; x-ray crystallography; medicinal chemistry
Impact Grant applications in preperation
Start Year 2014
 
Description SULSA-funded Collaboration with Dr Stuart McElroy 
Organisation University of Dundee
Country United Kingdom 
Sector Academic/University 
PI Contribution We established a high-throughput screening assay
Collaborator Contribution Dr McElroy helped us develop our HTS assay to make an application to the European Lead Factory for uHTS.
Impact We have now carried out uHTS with the European Lead Factory. Compounds are currently under development.
Start Year 2012